Ensemble Discovery
About
Ensemble develops Ensemblins to treat diseases by addressing drug targets that are currently inaccessible with small molecule drugs.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $15M
- Industries
- Biotechnology,Health Care,Medical Device
- Founded date
- Jan 1, 2002
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 12, 2007 | Series B | $15M | 2 | — | — | Detail |
| May 12, 2004 | Series A | $15M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
ARCH Venture Partners
|
— | Series B |
|
|
— | Series B |
